美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Direxion Daily Biotech Top 5 Bull 2X ETF

39.61

+1.052.72%

成交量：94

成交額：3,720

市值：297.11萬

市盈率：- -

高：39.61

開：38.56

低：39.61

收：38.56

52周最高：45.88

52周最低：25.71

股本：7.50萬

流通股本：7.50萬

量比：0.01

換手率：0.13%

股息：0.62

股息率：1.57%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

一周兩度受挫！諾華(NVS.US)心臟病重磅藥III期折戟，股價大跌安進(AMGN.US)「躺槍」

摩根大通投行聯席負責人：併購交易業務有望迎來創紀錄年份。

安進（AMGN）罕見病藥物Tavneos將於27年3月1日被徹底撤銷英國上市許可

高盛9月「確信名單」更新：美股納入福泰製藥(VRTX.US) 歐股力推萊茵、Adyen和塔蘭克斯

高盛9月「確信名單」更新：美股納入福泰製藥歐股力推萊茵、Adyen和塔蘭克斯

英國監管機構因數據不可靠，暫停安進公司Tavneos用於新患者

英國藥品與健康產品管理局：通知上市許可持有方，自9月1日起暫停新患者使用、供應及銷售Avacopan Vifor

特朗普政府將宣佈藥品定價協議

機構：爭奪天然氣資產推高併購交易規模創2013年以來新高

安進（AMGN）降脂藥Repatha新臨床數據：可降低未發生心梗或中風高危患者20%死亡風險

南京諾令生物科技股份有限公司向港交所提交上市申請書，獨家保薦人為建銀國際。

據港交所文件，維眸生物科技股份有限公司-B向港交所提交上市申請書。

美國食品藥品監督管理局（FDA）批准吉利德治療艾滋病的每日一次複方片劑

美國FDA批准吉利德科學Bixlenvo™上市：每日單片方案為病毒學抑制HIV成人患者提供新選擇，涵蓋複雜治療方案人群

英國股市——8月27日需關注的因素

阿斯利康的哮喘藥物Tezspire在食管炎晚期臨床試驗中達到了所有目標

Tezspire®在嗜酸性食管炎III期臨床試驗中展現積極成果，共同主要終點及所有關鍵次要終點全面達標

美股開盤｜三大指數升跌不一；Meta升逾3%、小鵬汽車升逾3%；生物科技股活躍

羅兵咸永道：上半年中國併購交易量7316宗創歷史新高預計下半年延續強勁勢頭

歐盟委員會擴大吉利德Trodelvy®在轉移性三陰性乳腺癌一線治療中的應用範圍，覆蓋所有PD-L1狀態

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/TBXU/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"TBXU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TBXU\",,,,,undefined,":{"symbol":"TBXU","market":"US","secType":"STK","nameCN":"Direxion Daily Biotech Top 5 Bull 2X ETF","latestPrice":39.6136,"timestamp":1789675200000,"preClose":38.5642,"halted":0,"volume":94,"delay":0,"changeRate":0.02721176635324987,"floatShares":75001,"shares":75001,"eps":0,"marketStatus":"盤前交易","change":1.0494,"latestTime":"09-18 05:47:31 EDT","open":38.5642,"high":39.6136,"low":39.6136,"amount":3720,"amplitude":0,"askPrice":62.98,"askSize":100,"bidPrice":15.94,"bidSize":100,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":39.6136,"sharesOutstanding":100001,"nav":38.569,"aum":2892712,"dividendRate":0.015697,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.5642,"preClose":39.6136,"latestTime":"16:10 EDT","volume":6,"amount":237.6816,"timestamp":1789675804466,"change":-1.0494,"changeRate":-0.026491,"amplitude":0},"volumeRatio":0.010386051604292897},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TBXU\",,,,,undefined,":{"symbol":"TBXU","floatShares":75001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.010386051604292897,"shares":75001,"dividePrice":0.6218,"high":39.6136,"amplitude":0,"preClose":38.5642,"low":39.6136,"week52Low":25.71,"pbRate":"--","week52High":45.88,"institutionHeld":0,"latestPrice":39.6136,"eps":0,"divideRate":0.015697,"volume":94,"delay":0,"ttmEps":0,"open":38.5642,"prevYearClose":31.065,"prevWeekClose":38.3601,"prevMonthClose":42.9245,"prevQuarterClose":32.1223,"fiveDayClose":38.8987,"twentyDayClose":44.7799,"sixtyDayClose":29.646},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TBXU\",params:#limit:5,,,undefined,":[{"date":"2026-06-23","symbol":"TBXU","amount":0.11101,"announcedDate":"2026-06-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-23","defaultRemindTime":1782221400000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-23","currency":"USD","dateTimestamp":1782187200000,"payDate":"2026-06-30"},{"date":"2026-03-24","symbol":"TBXU","amount":0.09893,"announcedDate":"2026-03-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-24","defaultRemindTime":1774359000000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-24","currency":"USD","dateTimestamp":1774324800000,"payDate":"2026-03-31"},{"date":"2025-12-23","symbol":"TBXU","amount":0.10111,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-31"},{"date":"2025-12-10","symbol":"TBXU","amount":0.31143,"announcedDate":"2025-12-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-10","defaultRemindTime":1765377000000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-17","payableDate":"2025-12-10","currency":"USD","dateTimestamp":1765342800000,"payDate":"2025-12-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TBXU\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-10","recordDate":"2025-12-10","paymentDate":"2025-12-17","value":0.31143,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-31","value":0.10111,"currency":"USD"},{"executeDate":"2026-03-24","recordDate":"2026-03-24","paymentDate":"2026-03-31","value":0.09893,"currency":"USD"},{"executeDate":"2026-06-23","recordDate":"2026-06-23","paymentDate":"2026-06-30","value":0.11101,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TBXU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TBXU\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665392789","title":"一周兩度受挫！諾華(NVS.US)心臟病重磅藥III期折戟，股價大跌安進(AMGN.US)「躺槍」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392789","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665392789?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 15:15","pubTimestamp":1788765302,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞士制药巨头诺华制药再遭临床试验打击——一周之内，该公司第二项重磅候选药物在后期研究中折戟。此次失利的是其潜在明星心脏病药物pelacarsen。受此消息影响，诺华在美上市股票上周五常规交易结束后一度下跌逾7%。开发类似心脏药物的安进股价上周五盘后也下挫近6%。诺华正寄望于一系列新药来支撑增长，以应对旗下多款重磅产品专利即将到期的压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","IE00B4R5TH58.HKD","LU2242652126.USD","BK4007","AMGN","LU2468319806.SGD","SG9999001440.SGD","LU1057294990.SGD","LU2089984988.USD","BK4566","LU0889565916.HKD","LU0320765489.SGD","BK4532","LU0070302665.USD","PJP","IBB","BBH","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU1023059063.AUD","IBBQ","LU1061106388.HKD","BK4578","LU0058720904.USD","MEDX","LU2242646821.SGD","LU0868494617.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00B2B36J28.USD","NVS","PBE","IE00BJT1NW94.SGD","PPH","LU2112291526.USD","LU0109394709.USD","TBXU","BK4139","IE0009355771.USD","BK4588","BK4599","BIB","BK4533","BK4581","LU1571399168.USD","BK4534","LU0208291251.USD","LU0122379950.USD","LU0211331839.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664463098","title":"摩根大通投行聯席負責人：併購交易業務有望迎來創紀錄年份。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664463098","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664463098?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 02:58","pubTimestamp":1788375516,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AAUM","BK4582","PGF","MMID","XLFI","VXF","RSPH","PSP","CANC","IBBQ","UYG","RFG","TMED","PBPH","GTPE","TBXU","FFSM","PEVC","IEFN","IYH","BK4588","ACTV","DFMC","BK4585","PRVT","MNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664194548","title":"安進（AMGN）罕見病藥物Tavneos將於27年3月1日被徹底撤銷英國上市許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2664194548","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664194548?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:59","pubTimestamp":1788350357,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英国药品监管机构MHRA宣布，暂停安进（AMGN）罕见病药物Avacopan Vifor（原商品名Tavneos）用于新患者，监管认定支撑该药物获批的关键临床试验数据已不可靠。该药2022年在英国获批，用于治疗两种罕见血管炎症自身免疫病。安进持有美国地区权益，由CSL集团（CSLLY）旗下CSLVifor负责英国等海外市场销售。新规9月1日落地，不再允许新患者启用该药物；为保障现有患者安全，设置6个月过渡用药期，2027年3月1日将彻底撤销其英国上市许可，现有患者可在此期间逐步更换替代治疗方案。安进方面公开表示不认可监管机构的决定，担忧该举措会对罕见病患者造成负面影响。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305627","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","BIB","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","PJP","IPOS","IE0009355771.USD","BK4533","AMGN","LU0320765992.SGD","BK4581","PBE","TBXU","LU1983299246.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","IE00B2B36J28.USD","LU2242646821.SGD","LU0889565916.HKD","LU1023059063.AUD","LU2089984988.USD","BK4139","AZNH","LU2242652126.USD","LU2112291526.USD","LU0122379950.USD","LU1061106388.HKD","LU2468319806.SGD","LU0868494617.USD","BK4599","BK4534","IBBQ","LU1057294990.SGD","BK4566","BBH","BK4585","LU0289739699.SGD","LU1571399168.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","BK4588","LU0058720904.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891714","title":"高盛9月「確信名單」更新：美股納入福泰製藥(VRTX.US) 歐股力推萊茵、Adyen和塔蘭克斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891714","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664891714?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:20","pubTimestamp":1788333621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GNMX","IDNA","IE0002141913.USD","LU0289739699.SGD","BK4585","LU2237438978.USD","LU0061475181.USD","TBXU","LU0096364046.USD","BBH","LU2237443549.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","LU1868836591.USD","BIB","LU1791807156.HKD","LU2456880835.USD","IE00BZ9MQY76.HKD","LU0868494708.USD","BK4127","LU0868494617.USD","LU1668664300.SGD","LU0251131958.USD","SG9999001176.SGD","IE0009355771.USD","IEV","LU2468319806.SGD","IBBQ","LU1674673691.USD","LU2471134523.USD","LU2462157665.USD","BK4533","BK4550","LU2471134952.CNY","VRTX","LU1868837300.USD","IBB","VXUS","LU0432979614.USD","IE00B19Z9P08.USD","LU1868836914.USD","IE00B19Z9Z06.USD","VGK","GSX","PBE","BK4588","LU0942090050.USD","SG9999001176.USD","LU2237443978.SGD","LU1144417596.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891705","title":"高盛9月「確信名單」更新：美股納入福泰製藥 歐股力推萊茵、Adyen和塔蘭克斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891705","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664891705?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:20","pubTimestamp":1788333621,"startTime":"0","endTime":"0","summary":"进入秋季，高盛对其美国及欧洲市场的“确信名单”进行了更新，为投资者指明当前最看好的股票方向。本次调整中，美国名单新增一只大型生物科技股，欧洲名单则迎来三家新面孔。美国名单：新增福泰制药，移除盈透证券在美国市场，高盛将 $福泰制药$纳入确信名单，同时移除了 $盈透证券$，调整后名单保留23只股票。高盛还表示，塔兰克斯的国际零售业务是被低估的增长引擎。","market":"us","thumbnail":"https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490866.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BFTCPJ56.SGD","IE0004091025.USD","LU2237443549.SGD","LU2456880835.USD","MSFW","IE00B19Z3581.USD","LU0432979614.USD","UNH","LU2265009873.SGD","DAL","IE0002270589.USD","LU2417539215.USD","LU1868837300.USD","LU1868836757.USD","LU2236285917.USD","LU2471134952.CNY","LU2750360641.GBP","SG9999001176.SGD","MSFT","MSFO","BIB","IBB","IBKR","PBE","WFC","LU2471134879.HKD","IDNA","COP","LU0109394709.USD","MSFD","BK4585","LU0345770993.USD","LU1069344957.HKD","MSFU","MSFX","MSFY","XYZY","VRTX","BK4532","MSFL","IBBQ","TBXU","LU0106831901.USD","LU2362541273.HKD","VXUS","IE00BJT1NW94.SGD","UNHW","GNMX","SG9999001176.USD","IE00B2B36J28.USD","XYZ","BBH","UNHG","VGK","XYZG","BK4567","IE0034235188.USD","BK4533","IE00BFXG1179.USD","LU2471134796.USD","UN","GSX","LU2471134523.USD","LU0889565916.HKD","UNHU","IEV","CRNX","EL","MSFC","BK4504","LU1868837136.USD","LU2468319806.SGD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664347855","title":"英國監管機構因數據不可靠，暫停安進公司Tavneos用於新患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2664347855","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664347855?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:15","pubTimestamp":1788261324,"startTime":"0","endTime":"0","summary":"英国监管机构因数据不可靠，暂停安进公司Tavneos用于新患者路透9月1日-英国药品监管机构周二暂停了安进公司旗下AMGN.O研发的罕见病药物Tavneos对新患者的使用和销售，称支持该药获批的主要研究结果不可靠。监管机构表示，由于主要临床试验的数据不可靠，该研究已无法证明该药有效，也无法证明其益处大于风险。Tavneos由ChemoCentryx公司研发，安进公司于2022年以37亿美元收购了该公司。欧洲委员会于8月撤销了Tavneos的批准，此前监管机构发现其关键试验数据不可靠。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4T44T10B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK7508","CSL.AU","BK4534","LU0289739699.SGD","LU0889565916.HKD","LU0320765992.SGD","LU1983299246.USD","BK7511","LU2242652126.USD","AMGN","IBBQ","IE00B4R5TH58.HKD","PJP","LU0122379950.USD","LU2468319806.SGD","LU1023059063.AUD","BK4533","BK4599","IE00B2B36J28.USD","LU2242646821.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","SG9999001440.SGD","TBXU","LU1061106388.HKD","PBE","IE00BJT1NW94.SGD","BIB","LU2112291526.USD","LU2089984988.USD","BK4588","BK4581","IE0002141913.USD","BK4585","BK7067","IBB","LU1057294990.SGD","BK7501","LU0109394709.USD","BBH","LU0868494617.USD","IE00BJJMRZ35.SGD","LU1571399168.USD","BK4139","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148791645","title":"英國藥品與健康產品管理局：通知上市許可持有方，自9月1日起暫停新患者使用、供應及銷售Avacopan Vifor","url":"https://stock-news.laohu8.com/highlight/detail?id=1148791645","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148791645?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 17:35","pubTimestamp":1788255329,"startTime":"0","endTime":"0","summary":"英国药品与健康产品管理局（MHRA）已正式告知上市许可持有方，关于暂停Avacopan Vifor用于新患者的使用、供应及销售的相关决定。该措施自9月1日起生效。此番调整涉及该药物的市场流通环节，意在规范其临床应用范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU2242646821.SGD","BK4533","BK4581","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0058720904.USD","IE00B2B36J28.USD","IE0009355771.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU2089984988.USD","PBE","LU0109394709.USD","LU0122379950.USD","BK4585","LU1023059063.AUD","LU0889565916.HKD","IBB","LU2468319806.SGD","LU1983299246.USD","BK4588","LU2112291526.USD","AMGN","BK4599","PJP","BBH","BIB","IE00BJJMRZ35.SGD","LU0868494617.USD","LU0289739699.SGD","TBXU","SG9999001440.SGD","LU2242652126.USD","LU1571399168.USD","BK4534","BK4139","IBBQ","BK4566","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664002674","title":"特朗普政府將宣佈藥品定價協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2664002674","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664002674?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 00:07","pubTimestamp":1788192474,"startTime":"0","endTime":"0","summary":"特朗普政府将宣布药品定价协议预计拜耳、武田、CSL以及中型生物技术公司将达成新协议路透此前曾报导，小型制药商认为参与其中的财务激励有限美国处方药价格往往是其他发达国家的近三倍路透8月31日-白宫一名官员表示，美国总统唐纳德·特朗普  预计将于周一宣布新一轮药品定价协议，这是旨在降低美国民众医疗保健成本举措的一部分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4T44S1CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","LU1623119135.USD","LU2265009873.SGD","LU2089283258.USD","LU2168564149.EUR","SG9999014880.SGD","OZEM","BK4581","IE00B19Z3581.USD","LU0882574139.USD","PPH","LU1868837300.USD","IXJ","XLV","LU0432979614.USD","SG9999002224.SGD","BK7067","ILDR","LU0385154629.USD","LU1066051498.USD","BK4566","LU2596442595.SGD","IE00B2B36J28.USD","IE00BJLML261.HKD","IE0002270589.USD","LU0820561909.HKD","LU0316494557.USD","LU0320765992.SGD","LU1093756168.USD","LU2089984988.USD","LU0889565916.HKD","IE0009355771.USD","CSL.AU","IE00B7KXQ091.USD","LU0689472784.USD","LU2168564495.EUR","LU0158827781.USD","LU1868836914.USD","BK7501","LU1366192091.USD","LU0106261372.USD","LU2491050154.USD","SG9999014906.USD","LU0823416689.USD","LU2361045086.USD","LU1023059063.AUD","IE00BJJMRY28.SGD","IE00BKPKM429.USD","LU1868836591.USD","SG9999001440.SGD","LLII","LU0198837287.USD","SG9999018857.SGD","LU2602419157.SGD","LU0323591593.USD","LU2023251221.USD","SG9999001176.SGD","LU1894683348.USD","IE00BWXC8680.SGD","IE0005OL40V9.USD","LU1057294990.SGD","BK4568","IE00BJJMRX11.SGD","SG9999018865.SGD","IYH","LU1267930730.SGD","ELIS","LU0345770308.USD","LU0985481810.HKD","IE00BFSS8Q28.SGD","BK7511","LU0158827948.USD","LU0306806265.USD","LU0882574055.USD","LU0238689110.USD","LU1323610961.USD","LU1868837136.USD","LU2471134879.HKD","LU2756315664.SGD","SG9999013999.USD","LU1035775433.USD","LU1712237335.SGD","LU2213496289.HKD","LU2361044949.HKD","LU0203201768.USD","IBBQ","LU2471134523.USD","LU2471134796.USD","LU2456880835.USD","LU0417517546.SGD","LU2237443978.SGD","LLYX","IE0004445239.USD","LU2087625088.SGD","LU0210536198.USD","LU2461242641.AUD","BK4534","IE00BLSP4239.USD","LU1127390331.HKD","IE00B19Z3B42.SGD","GDOC","LU0466842654.USD","LU0868494617.USD","JDOC","LU0256863902.USD","LU1093756325.SGD","IHE","LU2552382215.SGD","LU2237443465.HKD","LU0320765059.SGD","LU1979441026.SGD","LU1069344957.HKD","LU1548497426.USD","BK4139","LU2108987350.USD","LU2462591350.SGD","AMGN","IE00B4R5TH58.HKD","TMED","LU1061106388.HKD","LU0109394709.USD","LU2264538146.SGD","LU2417539215.USD","SGXZ57979304.SGD","BK4007","LU0006306889.USD","LU2111349929.HKD","BBH","LU2237443895.HKD","PBE","LU1720051108.HKD","04332","IE00BFTCPJ56.SGD","IE00B1XK9C88.USD","IE000M9KFDE8.USD","LU2237443382.USD","LU2168564065.EUR","PJP","LU2491050071.SGD","LU2211815571.USD","BK4516","LU1291159041.SGD","SG9999015978.USD","BK4533","LU2357305700.SGD","SGXZ81514606.USD","LU2552382132.HKD","BK7508","LU2324357040.USD","LU0345770993.USD","LLY","IBB","LU2361044865.SGD","LU1629891620.HKD","LU1983299246.USD","LU2746668974.SGD","LU2236285917.USD","LU0672654240.SGD","SGXZ51526630.SGD","THNR","IE00BKDWB100.SGD","IE00B3T34201.USD","IE00BBT3K403.USD","LU0225284248.USD","LU2756315318.SGD","LU0306807586.USD","BK4592","LU0094547139.USD","HRTS","LU0096364046.USD","SGXZ99366536.SGD","LU0353189680.USD","BK4588","LU2471134952.CNY","FHLC","LU0708995401.HKD","LU1974910355.USD","LU1804176565.USD","LU2242646821.SGD","LU2271345857.HKD","SG9999011175.SGD","LU0321505868.SGD","SG9999001176.USD","WDNA","LU2028103732.USD","LU1989771016.USD","MEDI","MEDX","BK4550","LU0943347566.SGD","LU2168563687.JPY","SG9999015945.SGD","LU0225283273.USD","LU2896262040.SGD","IE0004445015.USD","LU0354030438.USD","LU0122379950.USD","LU0471298694.HKD","LU2023250504.SGD","GB00BDT5M118.USD","LU0353189763.USD","MHIP","LU0109391861.USD","LU0823434583.USD","LU0133085943.USD","SGXZ31699556.SGD","SG9999003800.SGD","IE00BFSS7M15.SGD","IE00BN29S564.USD","IONS","LU0174119429.USD","LU0456855351.SGD","IE00B1BXHZ80.USD","IE00BJT1NW94.SGD","LU1280957306.USD","LU0061475181.USD","LU0234572021.USD","LU2237443549.SGD","LU2168564222.USD","LU0640476718.USD","BK4599","LU2237438978.USD","LU2468319806.SGD","ELIL","LU0079474960.USD","LU1064131342.USD","LU2106854487.HKD","LLYZ","IE00BK4W5L77.USD","LU0354030511.USD","LU0823434740.USD","IE00B775H168.HKD","LU0683600562.USD","CURE","IE00BJJMRZ35.SGD","LU0225771236.USD","LU1883839398.USD","CANC","FTXH","PFE","LU0787776722.HKD","LU0170899867.USD","LU0203202063.USD","BIB","LU1814569148.SGD","LU0114720955.EUR","RXL","IE00B4JS1V06.HKD","LU0097036916.USD","LU2462157665.USD","SG9999014914.USD","LU1571399168.USD","VHT","LU1232071149.USD","LU1720051017.SGD","LU2750360997.AUD","SG9999014898.SGD","LU0964807845.USD","TRUH","LU1894683264.USD","IE0001KFT4U8.USD","LU1988902786.USD","LU2746668461.USD","LU1917777945.USD","LU0321505439.SGD","LU1066053197.SGD","LU2237443622.USD","LU1145028129.USD","LU2112291526.USD","LU0820562030.AUD","LU2491049909.HKD","LU0256863811.USD","SG9999002232.USD","LU0786609619.USD","SG9999015952.SGD","LU0471298777.SGD","LU1868836757.USD","SG9999015986.USD","LU2552382058.USD","LU0058720904.USD","IE00BK4W5M84.HKD","LU2242652126.USD","TBXU","LU2023250330.USD","LU0289739699.SGD","LU0266013472.USD","LU1551013425.SGD","LU0820561818.USD","LU2089284900.SGD","AGNG","BK4585","LU2750360641.GBP","IE0002141913.USD","LU1551013342.USD","LU2360106947.USD","SG9999017495.SGD","LU2063271972.USD","LU1691799644.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663017770","title":"機構：爭奪天然氣資產推高併購交易規模創2013年以來新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2663017770","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663017770?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 22:52","pubTimestamp":1788187964,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CANC","USE","RSPH","BK4570","DFMC","BK4588","BOIL","PSP","IEFN","TMED","ERX","PXE","XLFI","KOLD","TBXU","XES","FCG","BK4585","IYH","UYG","FFSM","DRLL","PRVT","VDE","PEVC","FTXN","DBC","RFG","XOP","GUSH","AAUM","MMID","DBE","IEO","MNA","IBBQ","DIG","VXF","DRIP","WTIU","GTPE","PXJ","DUG","PBPH","IXC","ACTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663778550","title":"安進（AMGN）降脂藥Repatha新臨床數據：可降低未發生心梗或中風高危患者20%死亡風險","url":"https://stock-news.laohu8.com/highlight/detail?id=2663778550","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663778550?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 18:48","pubTimestamp":1788173287,"startTime":"0","endTime":"0","summary":"研究结果显示，对于既往未发生过心肌梗死或中风的高危成年患者，在接受他汀类或其他降脂疗法的基础上加用Repatha，可显著降低20%的全因死亡风险，同时有效降低心血管死亡率。数据显示，Repatha能在治疗开启最早6个月内降低心梗风险，且将患者低密度脂蛋白胆固醇中位数降低至45mg/dL，远优于安慰剂组的109mg/dL。此外，欧盟委员会已于2026年8月批准扩大Repatha在欧洲的适应症，用于确诊或高危确诊的动脉粥样硬化性心血管疾病成年患者降低心血管风险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/Mjk1NzA2YjQxMDg1MTQ0MjI1MzE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Mjk1NzA2YjQxMDg1MTQ0MjI1MzE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305491","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0058720904.USD","LU2242652126.USD","LU1023059063.AUD","LU0122379950.USD","LU0289739699.SGD","LU1983299246.USD","LU2468319806.SGD","BK4581","LU1061106388.HKD","PJP","IBB","BK4139","LU0320765992.SGD","IE00B4R5TH58.HKD","LU1571399168.USD","BK4533","IBBQ","BK4585","BK4599","BK4588","LU2242646821.SGD","TBXU","LU0109394709.USD","IE00BFTCPJ56.SGD","BK4534","PBE","IE00BJT1NW94.SGD","BK4566","LU0889565916.HKD","AMGN","LU2089984988.USD","IE0002141913.USD","SG9999001440.SGD","BIB","LU2112291526.USD","LU0868494617.USD","BBH","IE0009355771.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662091790","title":"南京諾令生物科技股份有限公司向港交所提交上市申請書，獨家保薦人為建銀國際。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662091790","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662091790?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 22:53","pubTimestamp":1787928801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BIOY","TBXU","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662942093","title":"據港交所文件，維眸生物科技股份有限公司-B向港交所提交上市申請書。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662942093","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662942093?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 20:52","pubTimestamp":1787921537,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BIOY","IPOS","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036374","title":"美國食品藥品監督管理局（FDA）批准吉利德治療艾滋病的每日一次複方片劑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036374","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036374?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 05:50","pubTimestamp":1787867453,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）批准吉利德治疗艾滋病的每日一次复方片剂路透8月27日-吉利德科学公司周四表示，美国食品和药物管理局已批准该公司研发的每日一次口服复方药GILD.O，用于治疗HIV病毒载量已降至极低水平的成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4S44O24V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","IBB","GILD","IE00B19Z3581.USD","IBBQ","IE00B3T34201.USD","LU1934455194.USD","BK4532","IE00B7SZLL34.SGD","LU0965509283.SGD","BIB","IE00BKVL7J92.USD","LU0114720955.EUR","BK4566","LU1571399168.USD","LU2468319806.SGD","IE0002270589.USD","BMED","MEDI","LU0889565916.HKD","SG9999015945.SGD","IE00BZ1G4Q59.USD","BK4139","LU1066053197.SGD","LU1934455277.USD","TMED","LU0861579265.USD","LU2112291526.USD","LU1061106388.HKD","LU0109394709.USD","SG9999015952.SGD","LU0965508806.USD","LU0823416689.USD","LU0965509101.SGD","BBH","LU2324357040.USD","LU1023059063.AUD","SG9999015986.USD","LU0058720904.USD","LU1778281490.HKD","TBXU","LU1037948541.HKD","LU0289739699.SGD","LU1037948897.HKD","SG9999015978.USD","BK4585","BK4568","LU1839511570.USD","LU1430594728.SGD","LU1674673691.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198194055","title":"美國FDA批准吉利德科學Bixlenvo™上市：每日單片方案為病毒學抑制HIV成人患者提供新選擇，涵蓋複雜治療方案人群","url":"https://stock-news.laohu8.com/highlight/detail?id=1198194055","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198194055?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 05:49","pubTimestamp":1787867358,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了吉利德科学旗下新药Bixlenvo。这款每日一次的单片制剂，专为病毒学抑制状态的HIV成人感染者设计——即便是那些正在接受复杂治疗方案的病患，也适用这一新选项。此项获批标志着HIV治疗领域又添一枚重要砝码。Bixlenvo以单片复方形式呈现，将给药频率与用药负担同步压缩，患者无需再面对繁琐的多药组合。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BBH","LU1934455277.USD","LU0289739699.SGD","LU2468319806.SGD","IE0002270589.USD","BK4583","TBXU","LU0058720904.USD","LU1571399168.USD","LU0859254822.USD","SG9999015978.USD","LU1430594728.SGD","LU2357627491.SGD","LU1585245621.USD","LU0861579265.USD","IE00B19Z3B42.SGD","LU1037948541.HKD","IE00B19Z3581.USD","IE00BSNM7G36.USD","LU0122379950.USD","LU0965509101.SGD","IE00BZ1G4Q59.USD","LU2089984988.USD","LU2087621335.USD","TMED","SG9999015986.USD","IE00BKVL7J92.USD","LU2112291526.USD","LU0889565916.HKD","LU1023059063.AUD","LU0882574055.USD","LU1674673428.USD","MEDI","LU0109394709.USD","LU1066053197.SGD","LU1839511570.USD","LU1061106388.HKD","SG9999015945.SGD","BK4578","GILD","IBBQ","LU0965509283.SGD","LU1674673691.USD","IBB","LU0114720955.EUR","LU0320765992.SGD","SG9999015952.SGD","IE00B7SZLL34.SGD","LU0965508806.USD","LU1778281490.HKD","LU1934455194.USD","LU0234570918.USD","BK4588","LU0823416689.USD","BIB","BK4550","BK4532","BK4585","BMED","LU0965509010.AUD","LU1037948897.HKD","IE00B3T34201.USD","LU1057294990.SGD","LU2324357040.USD","BK4139","BK4568","LU1934455863.HKD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775484","title":"英國股市——8月27日需關注的因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775484","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775484?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:53","pubTimestamp":1787813617,"startTime":"0","endTime":"0","summary":"更新 1-英国股市——8月27日需关注的因素新增新闻报导，更新期货行情路透8月27日-预计周四英国富时100指数.FTSE将低开，期货FFIc1下跌0.4%。*7月汽车产量：行业数据显示，受出口疲软及部分工厂提前进行夏季检修停产影响，英国7月汽车产量  同比下降11.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4T44O0JK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRU.UK","LU1355424745.HKD","LU0075056555.USD","LU0857590862.USD","GLEN.UK","LU1119994496.HKD","BBH","LU0122379950.USD","LU1104425308.USD","LU0889565916.HKD","IBBQ","LU1989771016.USD","TBXU","LU0949170426.SGD","LU0345777147.USD","LU0963555726.SGD","LU1057294990.SGD","AZN.UK","SG9999001176.SGD","LU1880407132.USD","AMGN","CRDA.UK","HFD.UK","LU0553294199.USD","LU1989772923.USD","PBE","BK4585","LU0345780950.USD","LU2293690082.USD","LU0868494617.USD","PPH.UK","SGXZ57979304.SGD","LU0211326755.USD","LU0310800379.SGD","LU0047713382.USD","LU0969580561.USD","LU1267930227.SGD","LU0792757196.USD","LU2089984988.USD","IE0034235188.USD","LU1267930573.SGD","BIB","BK4139","PJP","03165","BK5105","LU0171293334.USD","GAW.UK","LU0171276677.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662639773","title":"阿斯利康的哮喘藥物Tezspire在食管炎晚期臨床試驗中達到了所有目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2662639773","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662639773?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:08","pubTimestamp":1787810905,"startTime":"0","endTime":"0","summary":"阿斯利康的哮喘药物Tezspire在食管炎晚期临床试验中达到了所有目标路透8月27日-阿斯利康（AstraZeneca）AZN.L周四表示，其与安进（Amgen）AMGN.O联合开发的哮喘药物Tezspire，在治疗嗜酸性粒细胞性食管炎（一种食管的慢性炎症性疾病）的晚期临床试验中达到了主要和次要研究目标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4T44O0GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211327993.USD","LU0882574055.USD","LU1323610961.USD","BIB","LU0889565916.HKD","LU0960981461.USD","LU1015430645.USD","LU0158827948.USD","LU0823416689.USD","LU1989772840.SGD","AMGN","BK4139","IE00B2B36J28.USD","BK5011","LU0640478417.SGD","LU0757432116.USD","LU1481599808.USD","IBBQ","BK4599","LU0211328371.USD","LU0203345920.USD","LU2237443549.SGD","PBE","LU1064927863.SGD","03165","LU1273509221.SGD","PJP","LU0171276677.USD","LU0496365809.HKD","AZN.UK","LU1261432733.SGD","LU2125909247.SGD","LU2357627491.SGD","LU0526926950.USD","BBH","LU1196032939.SGD","LU0432979614.USD","IBB","LU1267930813.SGD","LU0949170426.SGD","TBXU","LU0011850046.USD","LU1119994496.HKD","IE00BFTCPJ56.SGD","LU0390134368.USD","LU2089284900.SGD","LU0557290698.USD","BK4588","LU1923622614.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146489142","title":"Tezspire®在嗜酸性食管炎III期臨床試驗中展現積極成果，共同主要終點及所有關鍵次要終點全面達標","url":"https://stock-news.laohu8.com/highlight/detail?id=1146489142","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146489142?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:00","pubTimestamp":1787810443,"startTime":"0","endTime":"0","summary":"Tezspire在针对嗜酸性食管炎的III期临床试验中取得了令人瞩目的积极结果。该试验不仅成功达到了共同主要终点，而且所有关键次要终点也悉数告捷。Tezspire的优异表现，标志着该领域治疗可能迎来重大变革。共同主要终点的同时达成，以及关键次要终点的全面覆盖，充分验证了Tezspire的疗效一致性和临床获益的广泛性。业内专家指出，Tezspire的这项研究成果，不仅巩固了其在炎症性疾病治疗领域的地位，更可能为后续的监管审批和市场推广奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0002141913.USD","LU1571399168.USD","LU2242652126.USD","AMGN","LU0320765992.SGD","LU1061106388.HKD","BK4581","LU2089984988.USD","LU1023059063.AUD","LU0122379950.USD","LU0109394709.USD","PJP","BK4534","IBB","PBE","LU0868494617.USD","IE00B4R5TH58.HKD","BK4599","SG9999001440.SGD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU2242646821.SGD","IBBQ","IE00B2B36J28.USD","LU1057294990.SGD","LU1983299246.USD","LU2112291526.USD","BK4139","BK4585","BK4588","LU0058720904.USD","BIB","LU0289739699.SGD","BK4566","IE0009355771.USD","TBXU","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106797728","title":"美股開盤｜三大指數升跌不一；Meta升逾3%、小鵬汽車升逾3%；生物科技股活躍","url":"https://stock-news.laohu8.com/highlight/detail?id=1106797728","media":"美股开盘","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106797728?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 21:30","pubTimestamp":1787751055,"startTime":"0","endTime":"0","summary":"投资者在英伟达财报公布前保持观望，市场情绪较为谨慎。公司拟通过部分赔偿及功能调整降低监管不确定性，股价盘前显著反弹。美国第二季度实际GDP年化季率维持1.5%。美国7月核心PCE同比增长3.3%，通胀黏性仍存。管理层警示激烈竞争对利润率造成压力，股价盘后回落近4%。营收及利润双双下滑，显示美国消费者支出放缓。公司宣称AI可服务的潜在市场规模高达30万亿美元，市场热议其估值合理性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOY","BK4505","XPEV","EVS.SI","TBXU","BK4526","LU0593848301.USD","09868","BK1575","BK1119","BK1539","BK1610","BK4099","BK4555","BK1588","BK1587","XPEG","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662784028","title":"羅兵咸永道：上半年中國併購交易量7316宗創歷史新高 預計下半年延續強勁勢頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2662784028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662784028?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 16:00","pubTimestamp":1787644859,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，普华永道指出，今年上半年，中国并购交易数量达7316宗，同比增加近30%，创下历史新高；交易总额同比增长56%至2416亿美元，为2023年以来最佳半年度表现。普华永道交易服务税务主管合伙人梅梁表示，预期中国并购市场在2026年下半年将延续强劲势头，全年交易总额有望实现同比增长。港交所仅上半年即录得51宗具私募股权背景的IPO，创下同期历史新高，超过半数为高科技企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CANC","GTPE","IYH","AAUM","MMID","IBBQ","TBXU","VXF","RFG","XLFI","PRVT","RSPH","BK4585","MNA","IEFN","PBPH","UYG","PEVC","ACTV","FFSM","TMED","DFMC","BK4588","PSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186632498","title":"歐盟委員會擴大吉利德Trodelvy®在轉移性三陰性乳腺癌一線治療中的應用範圍，覆蓋所有PD-L1狀態","url":"https://stock-news.laohu8.com/highlight/detail?id=1186632498","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186632498?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 18:32","pubTimestamp":1787567559,"startTime":"0","endTime":"0","summary":"欧盟委员会近日作出重要决定，将吉利德科学（Gilead Sciences）旗下重磅药物Trodelvy®的适用范围进一步拓宽。此次调整聚焦于转移性三阴性乳腺癌的一线治疗领域，且不再受限于患者的PD-L1表达状态。这一举措意味着，无论生物标志物检测结果如何，符合条件的患者均有望从该疗法中获益。此举不仅为临床医生提供了更为灵活的用药选择，也标志着Trodelvy®在肿瘤治疗版图中的地位得到显著提升。吉利德科学方面对此表示积极回应，认为该批准将助力满足更多患者未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1066053197.SGD","LU1778281490.HKD","IE00BKVL7J92.USD","IE00B19Z3581.USD","LU0882574055.USD","LU0122379950.USD","IE00B19Z3B42.SGD","LU0058720904.USD","MEDI","GILD","LU2087621335.USD","TMED","LU1571399168.USD","LU1674673691.USD","BK4578","BK4588","BK4532","BBH","LU2357627491.SGD","BK4585","IE0002270589.USD","BIB","LU1430594728.SGD","LU0320765992.SGD","LU1037948541.HKD","LU1934455277.USD","LU0965509283.SGD","LU2089984988.USD","IE00BZ1G4Q59.USD","BK4568","LU0114720955.EUR","LU1057294990.SGD","LU1839511570.USD","LU1066051498.USD","LU0289739699.SGD","LU1934455863.HKD","LU2112291526.USD","LU0859254822.USD","LU0965509101.SGD","LU0234570918.USD","LU1061106388.HKD","SG9999015986.USD","SG9999015945.SGD","IE00B7SZLL34.SGD","LU0823416689.USD","BK4566","LU0861579265.USD","SG9999015952.SGD","TBXU","LU0965509010.AUD","IE00B3T34201.USD","LU0889565916.HKD","LU2468319806.SGD","LU0965508806.USD","IBBQ","BK4583","IBB","SG9999015978.USD","LU1585245621.USD","LU2324357040.USD","LU1023059063.AUD","LU1037948897.HKD","LU1934455194.USD","BK4139","LU0109394709.USD","IE00BSNM7G36.USD","BK4550","BMED"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":3,"totalSize":163,"code":"91000000","status":"200"}]}}